6月18日，《关于深化科创板改革 服务科技创新和新质生产力发展的八条措施》（以下简称"科创板八 条"）发布满一周年。 一年来，监管部门持续提升科创板服务未盈利科技企业的制度包容性与精准性，发行承销、再融资等制度创新 落地实施，为未盈利科技型企业进一步构建适配发展路径。 记者获悉，监管部门从政策制定与审核执行两个维度同步发力，着力提升对未盈利企业"含科量"的精准识别能 力，严把发行上市准入关。 如在政策方面，证监会持续完善科创板科创属性评价标准，2024年进一步将研发投入门槛由6000万元提升至 8000万元，发明专利要求增至7项并强调产业化能力，以"硬科技"标尺引导企业夯实创新根基。 数据显示，"科创板八条"发布以来，先后有4家未盈利企业申报科创板IPO获得受理，6家上市时未盈利的科创 板公司再融资时适用"轻资产、高研发投入"标准，28单科创板并购交易涉及收购未盈利标的。 未盈利企业科创板IPO受理有序推进 去年6月19日，证监会发布的"科创板八条"明确提出，支持具有关键核心技术、市场潜力大、科创属性突出的 优质未盈利科技型企业在科创板上市，提升制度包容性。 "科创板八条"发布后，未盈利企业科创板IPO受理有 ...

6月18日，《关于深化科创板改革 服务科技创新和新质生产力发展的八条措施》（以下简称"科创板八条"）发布满一 周年。 一年来，"科创板八条"各项改革举措已基本落地，配套制度有序推出，典型案例渐次落地，政策效应日益显现。 再融资方面，"轻资产、高研发"认定标准正式落地，鼓励科创企业加大研发投入。 目前，已有9家科创板企业适用该标准 披露再融资相关公告，合计拟融资近250亿元。华泰联合证券有限责任公司执行委员会委员、大健康行业部主管高元接受 证券时报记者采访时表示，科创板公司多聚焦技术密集型领域，具有研发投入大、周期长等特点，"轻资产、高研发投 入"的认定从制度上降低了募集资金的使用限制，提高了募集资金的使用效率。 并购重组制度机制持续优化。 2025年5月，新修订的《上市公司重大资产重组管理办法》正式发布，上交所配套修订并 发布重大资产重组审核规则，新增重组简易审核程序；2025年4月，上交所修订发布《科创板股票上市规则》，同步完 善控股股东限售期转让股份豁免情形，为吸收合并上市不满3年上市公司留足空间。 | P | | | | | --- | --- | --- | --- | | 1 | 11 | x | ...

● 本报记者 黄一灵 《关于深化科创板改革 服务科技创新和新质生产力发展的八条措施》发布一年来，各项配套政策渐次 落地、科创企业资本市场工具箱持续扩容，为壮大耐心资本、优化新股发行秩序、助力科创企业加大研 发投入、加快培育新质生产力提供有力的政策支撑。 业内人士认为，创新和完善制度一直是科创板建设的主线，在科创板这块制度改革"试验田"里构建新的 制度体系，既可以满足市场需要，又可以为存量市场改革提供有益借鉴。可以预期的是，科技创新永无 止境，科创板制度改革也会不断深化，将为各类科创企业融资提供更加便利高效的支持。 强化科创板价值发现功能 "科创板八条"提出，开展深化发行承销制度试点。随后，科创板先行先试3%的最高报价剔除比例、新 股市值配售安排等一系列发行承销制度规则出台，优化了新股发行秩序，进一步强化科创板的价值发现 功能。 2024年6月，上交所明确了在科创板试点统一执行3%的最高报价剔除比例的政策。新股发行定价是市场 各方博弈的关键环节，而最高报价剔除机制是在新股发行定价过程中避免极端高报价干扰发行秩序、促 进网下投资者理性报价的一项重要安排。某头部基金公司相关人士在接受中国证券报记者采访时表示， 3% ...

Core Viewpoint - The release of the "Eight Measures for the Sci-Tech Innovation Board" by the China Securities Regulatory Commission marks a new phase in the reform of the Sci-Tech Innovation Board, aimed at supporting hard technology enterprises and optimizing the capital market ecosystem [1] Group 1: Support for Unprofitable Enterprises - The "Eight Measures" explicitly support unprofitable enterprises with key technologies and market potential to go public, allowing for a smoother IPO process [2] - As of May 2024, 54 unprofitable companies have been listed on the Sci-Tech Innovation Board, with a total revenue exceeding 170 billion yuan, reflecting a 24% year-on-year growth [2] - The cumulative net profit of these companies has improved, with a 36% reduction in losses year-on-year [2] Group 2: New Listing and Fundraising - Since the release of the "Eight Measures," 15 new companies have been listed, raising a total of 12.4 billion yuan, focusing on strategic emerging industries [3] - The introduction of a 3% maximum price exclusion ratio has optimized the new stock issuance order, ensuring a more reasonable pricing mechanism [4] Group 3: Financing and Investment - The "Eight Measures" have led to the establishment of standards for "light assets and high R&D investment," encouraging companies to allocate more resources to R&D [6] - Nine companies have applied under this standard, seeking nearly 25 billion yuan in financing, primarily in the biopharmaceutical and semiconductor sectors [6] Group 4: Mergers and Acquisitions - The "Eight Measures" have significantly supported mergers and acquisitions, with over 110 new transactions reported since the measures were implemented, totaling over 140 billion yuan [7] - Innovative cases such as the first directed convertible bond restructuring and various acquisition types have emerged, enhancing market diversity [7] Group 5: Regulatory Framework - The regulatory framework for the Sci-Tech Innovation Board has been continuously optimized, with nearly 60 announcements made to improve the rules and guidelines [8] - The establishment of the Shanghai Arbitration Commission's Securities Arbitration Center aims to provide efficient dispute resolution mechanisms for financial cases [8]

6月18日，《关于深化科创板改革服务科技创新和新质生产力发展的八条措施》（以下简称"科创板八 条"）发布满一周年。一年来，"科创板八条"各项改革举措已基本落地，配套制度有序推出，典型案例 渐次落地，政策效应日益显现。 配套制度有序推出 一年来，监管与市场协同发力，推动"科创板八条"从纸面走向实践，8方面30余项改革举措有序推出， 涉及发行承销、再融资、并购重组等制度创新。 其中，发行承销方面，上交所即明确在科创板试点统一执行3%的最高报价剔除比例，进一步加大网下 报价约束。一位市场人士向记者表示，规则实施后，剔除了部分策略性报价的投资者，并对买方整体报 价心理产生影响，减少了网下投资者"搭便车"报高价冲动。 截至目前，已有15只科创板新股适用3%的最高报价剔除比例。从报价来看，整体审慎合理，极端高价 行为有所缓解。 科创板新股网下认购须持有600万元科创板市值、优化未盈利企业新股发行网下配售与锁定安排等规则 也陆续推出，有助于引导资金长期持有科创板公司股票，进一步引导树立价值投资、长期投资理念。 再融资方面，"轻资产、高研发"认定标准正式落地，鼓励科创企业加大研发投入。目前，已有9家科创 板企业适用该标准披露 ...

Core Viewpoint - The implementation of the "Eight Measures for Deepening the Reform of the Sci-Tech Innovation Board" has significantly enhanced the support for unprofitable technology companies, facilitating their listing and financing opportunities on the Sci-Tech Innovation Board [1][2][3]. Group 1: Unprofitable Companies and IPOs - Since the release of the "Eight Measures," four unprofitable companies have successfully submitted their IPO applications to the Shanghai Stock Exchange [3][6]. - The recent acceptance of the IPO application from Zhaoxin Integrated, a leading domestic CPU manufacturer, marks another step forward in the orderly progress of unprofitable companies' IPOs on the Sci-Tech Innovation Board [2][3]. Group 2: Policy Enhancements and Standards - The China Securities Regulatory Commission (CSRC) has emphasized the importance of focusing on sectors with active technological innovation and has improved the evaluation standards for the Sci-Tech attributes of companies [3][4]. - In 2024, the R&D investment threshold for companies will be raised from 60 million to 80 million yuan, and the requirement for invention patents will increase to seven, emphasizing the need for industrialization capabilities [3][4]. Group 3: Support for R&D and Financing - The Shanghai Stock Exchange has introduced a "light asset, high R&D investment" standard to enhance transparency and predictability in refinancing for technology companies, with nine companies already disclosing refinancing plans totaling nearly 25 billion yuan [4][6]. - Dize Pharmaceutical became the first company to successfully complete refinancing under the new standard, highlighting the importance of this policy for sustaining R&D investments [4]. Group 4: Performance of Unprofitable Companies - As of May 2025, the Sci-Tech Innovation Board has supported 54 unprofitable companies, with a total revenue exceeding 170 billion yuan, reflecting a 24% year-on-year growth [6]. - Among these companies, 22 have achieved their first profit post-IPO, indicating a significant improvement in operational efficiency [6]. Group 5: Future Outlook - The continued implementation of the "Eight Measures" is expected to enable more unprofitable companies with core technologies to overcome capital constraints, thereby enhancing China's strategic position in the new technological revolution [7].

6月16日，汇添富上证科创板新材料交易型开放式指数证券投资基金正式在上海证券交易所（以下简 称"上交所"）挂牌上市交易。这一产品的顺利上市，为市场开辟了精准锚定新材料领域的专业化投资新 路径。 这也正是对《关于深化科创板改革服务科技创新和新质生产力发展的八条措施》（以下简称"科创板八 条"）政策要求的生动实践。2024年6月19日，中国证监会发布的"科创板八条"，明确提出"持续丰富科 创板指数品种""优化科创板宽基指数产品常态化注册机制"等核心举措，以发挥资本市场功能，更好服 务中国式现代化大局。 "科创板八条"实施以来，资本市场投资工具矩阵加速完善，科创板ETF产品数量和规模实现双突破，有 效引导金融"活水"流向"硬科技"领域。据上交所官网数据统计，自"科创板八条"发布以来，截至6月17 日，已新增57只科创板ETF上市，沪市科创板ETF总数达88只，产品总规模超2500亿元。 展望未来，上交所相关负责人表示，将继续推动科创板改革走深走实，持续加强与市场各方的沟通交 流，及时回应市场关切，凝聚合力，推动指数化投资生态向更高质量、更具韧性的方向迈进，为资本市 场的健康稳定发展注入持久动力。 科创板指数持续"上 ...

科创50指数今日下跌0.80%，报收963.08点，科创板全日成交量26.14亿股，成交额856.04亿元，加权平 均换手率为1.52%。 证券时报·数据宝统计显示，今日可交易科创板股中，237只股收盘上涨，涨幅在5%至10%的有7只，收 盘下跌的有346只，跌幅超10%的有2只。 科创板股换手率区间分布显示，换手率超过20%的有3只，换手率10%~20%的有10只，换手率5%~10% 的37只，换手率3%~5%的77只，换手率1%~3%的279只，换手率不足1%的有182只。 换手率最高的是金橙子，该股今日收盘上涨0.68%，全天换手率50.45%，成交额5.62亿元，其次是信宇 人，该股今日收盘下跌0.08%，全天换手率31.87%，成交额4.48亿元，换手率居前的还有海正生材、航 天南湖、青云科技等，换手率分别为22.73%、18.34%、15.01%。 统计显示，换手率超5%的高换手率个股中，影石创新为上市5日内的新股。 市场表现看，换手率超5%的个股中，今日上涨的有23只，涨幅居前的有艾为电子、先惠技术、联赢激 光等，分别上涨6.58%、6.25%、4.81%。跌幅居前的有科兴制药、中邮科技、华纳药 ...

Group 1 - The Invesco Great Wall SSE STAR Market 200 Index Fund has been launched for public offering from June 17, 2025, to September 16, 2025, with a minimum fundraising target of 200 million shares [2][3] - The fund aims to track the SSE STAR Market 200 Index, which selects 200 securities with smaller market capitalization and better liquidity from the STAR Market [2] - The fund's management fee is set at an annual rate of 0.15% based on the previous day's net asset value [3] Group 2 - The proposed fund manager, Gong Lili, has 14 years of experience in the securities and fund industry and has managed 14 funds with a total scale exceeding 30 billion yuan [4][5] - Gong Lili currently manages the Invesco Great Wall CSI A500 ETF, which has decreased by 0.7% year-to-date but outperformed its benchmark by 0.71 percentage points [6] - The Invesco Great Wall National Index Hong Kong Stock Connect Low Volatility ETF managed by Gong Lili has achieved a year-to-date return of 14.87%, exceeding its benchmark by over 1 percentage point [8]

Core Viewpoint - The implementation of the "K8 Measures" has led to a renewed focus on the fifth listing standard for unprofitable biotech companies on the STAR Market, aiming to enhance the financing environment for innovative drug firms and shift A-share valuation logic towards "technological value" and "commercial prospects" [1][5][15] Group 1: K8 Measures and STAR Market - The "K8 Measures" were introduced by the China Securities Regulatory Commission (CSRC) to support high-quality, unprofitable tech companies with key technologies and market potential to list on the STAR Market [1] - Since the introduction of the K8 Measures, two unprofitable hard tech companies have been accepted for listing, but the specific "Standard Five" for unprofitable innovative drug companies has yet to be activated [1][3] - The CSRC has reiterated its commitment to promoting the new cases under the fifth listing standard, which is expected to accelerate the financing pace for biotech companies [1][3] Group 2: Impact on Biotech Companies - Biotech companies, particularly innovative drug firms, face longer investment periods and greater uncertainty due to strict approval processes, making them highly dependent on capital [1][5] - The fifth listing standard has previously allowed 20 unprofitable biotech companies to list, with 19 of them successfully bringing 45 self-developed drugs/vaccines to market [3][5] - The introduction of the fifth standard has significantly shortened the capital cycle for these companies and has contributed to the prosperity of the biopharmaceutical primary market [3][5] Group 3: Commercialization and Financial Performance - As of 2024, the 20 companies that listed under the fifth standard collectively achieved revenues of 14.21 billion yuan, a year-on-year increase of 44.17%, with four companies expected to surpass 1 billion yuan in revenue in the coming years [12] - Companies like Ailis and Shenzhou Cell have reported significant revenue growth and profitability, attributing their success to continuous R&D investment and effective commercialization strategies [12][13] - The revised "STAR Market Attribute Evaluation Guidelines" for 2024 emphasize the importance of commercialization capabilities and revenue growth for companies seeking to list [11] Group 4: Future Prospects and Challenges - The market is keenly observing which companies will benefit first from the reactivation of the fifth listing standard, with five companies currently under review [14] - Companies with strong technological innovation capabilities and significant market potential are expected to be the first beneficiaries of the new standard [14][15] - The fifth listing standard presents both opportunities and challenges for unprofitable companies, requiring them to demonstrate their technological strengths and market potential despite not being profitable [15]